Monoclonal antibodies in the treatment of leukemia

Susan O'Brien; Maher Albitar; Francis J. Giles

doi:10.2174/156652405774641089

Monoclonal antibodies in the treatment of leukemia

Susan O'Brien
, Maher Albitar
, Francis J. Giles

The University of Texas Health Science Center at Houston

Research output: Contribution to a Journal (Peer & Non Peer) › Review article › peer-review

6 Citations (Scopus)

Abstract

MoAb-based therapies are evolving into the first broad-spectrum class of targeted anti-leukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAb's available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.

Original language	English
Pages (from-to)	663-675
Number of pages	13
Journal	Current Molecular Medicine
Volume	5
Issue number	7
DOIs	https://doi.org/10.2174/156652405774641089
Publication status	Published - Nov 2005
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2174/156652405774641089

Cite this

@article{d9ebffc64046417299b75b417d5b391c,

title = "Monoclonal antibodies in the treatment of leukemia",

abstract = "MoAb-based therapies are evolving into the first broad-spectrum class of targeted anti-leukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAb's available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.",

author = "Susan O'Brien and Maher Albitar and Giles, \{Francis J.\}",

year = "2005",

month = nov,

doi = "10.2174/156652405774641089",

language = "English",

volume = "5",

pages = "663--675",

journal = "Current Molecular Medicine",

issn = "1566-5240",

publisher = "Bentham Science Publishers",

number = "7",

}

TY - JOUR

T1 - Monoclonal antibodies in the treatment of leukemia

AU - O'Brien, Susan

AU - Albitar, Maher

AU - Giles, Francis J.

PY - 2005/11

Y1 - 2005/11

N2 - MoAb-based therapies are evolving into the first broad-spectrum class of targeted anti-leukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAb's available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.

AB - MoAb-based therapies are evolving into the first broad-spectrum class of targeted anti-leukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAb's available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.

UR - https://www.scopus.com/pages/publications/29244483950

U2 - 10.2174/156652405774641089

DO - 10.2174/156652405774641089

M3 - Review article

SN - 1566-5240

VL - 5

SP - 663

EP - 675

JO - Current Molecular Medicine

JF - Current Molecular Medicine

IS - 7

ER -

Monoclonal antibodies in the treatment of leukemia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this